Pinsent Masons advises Horizon 3 Healthcare on investment in Xeltis
04 Aug 2026 | 02:22 am |
Multinational law firm Pinsent Masons has advised Horizon 3 Healthcare as lead investor in an additional €20.5 million funding round for Xeltis, a clinical-stage medtech company developing transformative implantable medical devices.
The financing will support the advancement of Xeltis' aXess vascular access conduit toward US Food and Drug Administration (FDA) approval and commercial launch in the United States, while also supporting the continued development of the company's restorative cardiovascular technologies.
Horizon 3 led the round alongside a syndicate of existing and new investors, further strengthening Xeltis' position as it progresses the commercialisation of its pioneering endogenous tissue restoration platform.
The Pinsent Masons team was led by Melbourne-based corporate partner Andrew Fisken, with support from lawyers across APAC and Europe.
Commenting on the transaction, Andrew said: 'We are delighted to have advised our longstanding client Horizon 3 Healthcare on this strategic investment in Xeltis. The transaction highlights the continued investor confidence in innovative healthcare and medical technology businesses that have the potential to deliver meaningful clinical outcomes for patients globally. We look forward to seeing Xeltis continue to advance its groundbreaking technology towards regulatory approval and commercialisation in the United States and Europe.'
Key Contacts
Latest press releases
Show me all press releasesPinsent Masons announces FY26 results
Multinational law firm Pinsent Masons has today announced its unaudited financial results for the year ending 30 April 2026. The firm has generated a revenue increase of 3.3% to £703m. Profit per equity partner is £740k.
Pinsent Masons advises MJM Group on another M&A transaction in the Polish insurance sector
Multinational law firm Pinsent Masons has advised MJM Group, one of the leading brokerage groups in the insurance and reinsurance market, on the acquisition of a 100% stake in Certo Broker and XILIUM. Certo Broker specialises in the distribution of group and health insurance products, while XILIUM provides a digital platform for the administration of group life insurance programmes and health insurance policies.
Pinsent Masons advises Nichols plc on Vit Hit acquisition
Multinational law firm Pinsent Masons has advised British multinational soft drinks company Nichols plc (Nichols) on its acquisition of Vit Hit Limited (VITHIT) for €75 million.
People who viewed this press release also viewed
Show me all press releasesPinsent Masons advises FTI Consulting on sale of CX Lavender key client business to Omnicom Oceania
Multinational law firm Pinsent Masons has advised FTI Consulting, in its capacity as administrators of the CX Lavender group, on the sale of the company's key client-related business and associated workforce to Omnicom Oceania via its subsidiary, Clemenger BBDO Pty Ltd. The transaction completed in Q2 2026.
Pinsent Masons elects John Maciver as Senior Partner
Multinational law firm Pinsent Masons has elected John Maciver as Senior Partner.
Pinsent Masons strengthens its competition law practice with the appointment of Christian Peeters
Multinational law firm Pinsent Masons is strengthening its Antitrust, Competition & Trade practice at its Dusseldorf/Germany office with the appointment of Christian Peeters, LL.M., effective 1 July 2026.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on
Location contacts
Europe: [email protected]
Asia: [email protected]
Middle East: [email protected]
Australia: [email protected]